What is the time taken for digoxin to reach steady state concentration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Time to Reach Steady State Concentration for Digoxin

Digoxin reaches steady state concentration in approximately 5 half-lives, which equates to 7-10 days in patients with normal renal function. 1

Pharmacokinetic Profile of Digoxin

Digoxin has the following key pharmacokinetic properties:

  • Elimination half-life: 36-48 hours in patients with normal renal function 1, 2
  • Bioavailability: 60-80% for oral formulations 1, 3
  • Protein binding: Only 20-30% (unlike digitoxin which is 97% bound) 2, 3
  • Excretion: Primarily renal (50-70% excreted unchanged in urine) 1, 3

Factors Affecting Time to Steady State

Renal Function

  • The time to reach steady state is directly proportional to renal function
  • In patients with renal impairment, half-life can be prolonged to 3.5-6 days 4
  • In anephric patients, half-life can reach approximately 5 days 2
  • Calculation: Steady state = 5 × half-life

Age

  • Elderly patients (>70 years) often have decreased renal function even with normal serum creatinine levels
  • This results in longer time to reach steady state concentration 4
  • Newborns, despite higher serum digoxin levels, have a mean half-life of approximately 30 hours, similar to adults with normal renal function 5

Clinical Implications

Loading Dose Considerations

  • If rapid digitalization is required, a loading dose may be administered
  • Loading dose should be given in divided portions, with roughly half as the first dose 6
  • Additional fractions may be given at 6-8 hour intervals with careful clinical assessment 6

Maintenance Dosing

  • Maintenance dosing should begin after loading or can be used for gradual digitalization
  • Steady state will be achieved in approximately 5 half-lives (7-10 days in normal renal function) 6
  • Serum concentration measurements should be taken just before the next scheduled dose or at least 6-8 hours after the last dose 6

Monitoring Recommendations

Timing of Serum Level Measurements

  • To accurately assess steady state concentrations, samples should be taken:
    • Just before the next scheduled dose (trough level)
    • At least 6-8 hours after the last dose if pre-dose sampling is not possible 6
    • After 5 half-lives have elapsed (typically 7-10 days on a stable dose)

Therapeutic Range

  • Therapeutic serum concentration range: 0.5-0.9 ng/mL 7
  • Toxicity is associated with levels >2.0 ng/mL 7
  • Clinical response should always be considered alongside serum levels 6

Common Pitfalls to Avoid

  1. Failure to adjust for renal function: Patients with impaired renal function will take significantly longer to reach steady state and require lower maintenance doses.

  2. Premature serum level assessment: Checking levels before steady state is reached (before 5 half-lives) may lead to inappropriate dose adjustments.

  3. Ignoring electrolyte status: Hypokalemia and hypomagnesemia can sensitize the myocardium to digoxin effects, potentially leading to toxicity even at therapeutic levels 7.

  4. Not accounting for drug interactions: Certain medications (like amiodarone and dronedarone) can significantly increase digoxin levels and require dose adjustments 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacokinetics, bioavailability and serum levels of cardiac glycosides.

Journal of the American College of Cardiology, 1985

Research

Clinical pharmacokinetics of digoxin.

Clinical pharmacokinetics, 1977

Research

Serum digoxin concentration and half-life in newborn.

Klinische Wochenschrift, 1976

Guideline

Management of Breathlessness in Patients Taking Digoxin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.